Regulus Presents New Preclinical Data on miR-21 at Kidney Week 2012
-Regulus, in partnership with Sanofi, is developing novel anti-fibrotic
therapies targeting microRNAs-
LA JOLLA, Calif., Nov. 3, 2012
LA JOLLA, Calif., Nov. 3, 2012 /PRNewswire/ -- Regulus Therapeutics Inc.
(NASDAQ:RGLS), a biopharmaceutical company leading the discovery and
development of innovative medicines targeting microRNAs, today announced that
new preclinical data targeting microRNA-21 (miR-21) will be presented at 10:00
a.m. PDT on November 3, 2012 in a late-breaking poster session at the American
Society of Nephrology's Kidney Week 2012, meeting in San Diego, CA, October
30—November 4, 2012.
Late-Breaker Poster Presentation on miR-21 - November 3, 2012 10:00 a.m. PDT
- Anti-miR-21 Protects Collagen IVα(3) Deficient Mice from Progression of
Regulus scientists and its collaborator, Jeremy Duffield M.D., Ph.D.,
Associate Professor of Medicine in the Division of Nephrology at the
University of Washington, will present data demonstrating that therapeutic
oligonucleotides targeting miR-21 (anti-miR-21) reduces the severity of
fibrosis and improves renal function in a rodent model of Alport syndrome.
Regulus' miR-21 therapeutic development program, which is partnered with
Sanofi, is currently in preclinical testing for both kidney fibrosis and
"We are pleased to present at Kidney Week and believe these data further
validate that anti-miR-21 is a potential new therapy for human kidney
disease," said Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus.
"We're making good progress toward the selection of an anti-miR-21 clinical
development candidate and are excited about the potential to bring this
innovative treatment to patients with fibrotic diseases."
The abstract can be accessed at Regulus' website, http://www.regulusrx.com, in
the Publications page.
Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading
the discovery and development of innovative medicines targeting microRNAs.
Regulus is leveraging a mature therapeutic platform based on technology that
has been developed over 20 years. Regulus works with a broad network of
academic collaborators and leverages the oligonucleotide drug discovery and
development expertise of its founding companies, Alnylam Pharmaceuticals
(NASDAQ:ALNY) and Isis Pharmaceuticals (NASDAQ:ISIS). Regulus is advancing
microRNA therapeutics toward clinical development in several areas, including
oncology, fibrosis, hepatitis C and metabolic diseases. Regulus has formed
strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a
research collaboration with Biogen Idec.
For more information, please visit http://www.regulusrx.com.
Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements
associated with Regulus' expectations regarding future therapeutic and
commercial potential of Regulus' business plans, technologies and intellectual
property related to microRNA therapeutics being discovered and developed by
Regulus. Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or implied by such
forward-looking statements. Words such as "believes," "anticipates," "plans,"
"expects," "intends," "will," "goal," "potential" and similar expressions are
intended to identify forward-looking statements. These forward-looking
statements are based upon Regulus' current expectations and involve
assumptions that may never materialize or may prove to be incorrect. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of various risks
and uncertainties, which include, without limitation, risks associated with
the process of discovering, developing and commercializing drugs that are safe
and effective for use as human therapeutics, and in the endeavor of building a
business around such drugs. These and other risks concerning Regulus'
programs are described in additional detail in Regulus' SEC filings. All
forward-looking statements contained in this press release speak only as of
the date on which they were made. Regulus undertakes no obligation to update
such statements to reflect events that occur or circumstances that exist after
the date on which they were made.
SOURCE Regulus Therapeutics Inc.
Contact: Amy Conrad, Director, Investor Relations and Corporate
Communications, +1-858-202-6300, email@example.com; David Schull, Media,
Russo Partners, +1-212-845-4271, firstname.lastname@example.org
Press spacebar to pause and continue. Press esc to stop.